Anti-IL-5 biologics and rheumatoid arthritis: a single-centre 500 patient year exposure analysis
Authors' conclusion
Although ACPA positive RA has now been reported in a handful of case reports, we noted a very low rate of evolution into RA or inflammatory arthritis, at least in the short-medium term under anti-IL-5 therapy.
Study context
- Population
- All patients currently receiving mepolizumab or benralizumab for severe asthma, Leeds Teaching Hospitals NHS Trust Respiratory Servicemean 3.5 years on therapy
- Participants
- 142 participants
- Exposure
- Mepolizumab vs benralizumab
- Mepolizumabn = 89
- Benralizumabn = 53
- Outcome
- Prevalence of inflammatory rheumatological disease (incl. RA) following initiation of anti-IL-5 therapy
Methodological detailssingle-centre, audit
- Single-centre
- Audit
Main finding
As reported in the abstract
Formal diagnosis of RA after initiation of anti-IL-5 therapy · mean duration of 3.5 years on therapy
Mepolizumab
1
events
- Only one patient (on mepolizumab) received a formal diagnosis of rheumatoid arthritis (RA), with raised acute phase reactants and newly positive anti-CCP antibody (ACPA) and RF
- 1
- New arthralgias
- 17
Observational data: associations, not effects.
Further findings
Events
| Outcome | Mepolizumab | Benralizumab |
|---|---|---|
| New arthralgias | 9 | 8 |
- New arthralgias — Total patients with new arthralgias
- 17
Original publication
Anti-IL-5 biologics and rheumatoid arthritis: a single-centre 500 patient year exposure analysis. RMD Open. Published 19 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →